Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)

Cottrell et al. (Wed,) studied this question.

www.synapsesocial.com/papers/69df052cacbf09c32e61403b — DOI: https://doi.org/10.1093/annonc/mdy218

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab· 2014 · 2,203 citations
2. Neoadjuvant Trials Could Speed Up Drug Approvals· 2014 · 4 citations
3. Histologic Assessment of Non–Small Cell Lung Carcinoma after Neoadjuvant Therapy· 2003 · 54 citations
4. STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors· 2014 · 1,804 citations
5. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group· 2015 · 282 citations